These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9825249)

  • 1. [Positive and negative symptoms in chronic schizophrenic patients under maintenance therapy with flupenthixol decanoate for a twelve month perioid].
    Pach J; Finkbeiner T; Glaser T; Haug J; Osterheider M; Tegeler J
    Fortschr Neurol Psychiatr; 1998 Oct; 66(10):442-9. PubMed ID: 9825249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms.
    Ruhrmann S; Kissling W; Lesch OM; Schmauss M; Seemann U; Philipp M
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1012-22. PubMed ID: 17412473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia].
    Philipp M; Lesch OM; Schmauss M; Dose M; Glaser T
    Psychiatr Prax; 2003 May; 30 Suppl 2():S94-6. PubMed ID: 14509050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study.
    Levin FR; Evans SM; Coomaraswammy S; Collins ED; Regent N; Kleber HD
    Am J Drug Alcohol Abuse; 1998 Aug; 24(3):343-60. PubMed ID: 9741939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
    Kong DS; Yeo SH
    Pharmatherapeutica; 1989; 5(6):371-9. PubMed ID: 2687894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose zotepine in the maintenance treatment of schizophrenia.
    Fleischhacker WW; Stuppäck C; Barnas C; Unterweger B; Hinterhuber H
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):61-3. PubMed ID: 2883685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.
    Henderson DC; Goff DC
    J Clin Psychiatry; 1996 Sep; 57(9):395-7. PubMed ID: 9746446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of maprotiline combined with conventional neuroleptics against negative symptoms of chronic schizophrenia.
    Yamagami S; Soejima K
    Drugs Exp Clin Res; 1989; 15(4):171-6. PubMed ID: 2570687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
    Youssef HA
    Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of negative symptoms of schizophrenia to neuroleptic treatment.
    Serban G; Siegel S; Gaffney M
    J Clin Psychiatry; 1992 Jul; 53(7):229-34. PubMed ID: 1639741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: a prospective open trial.
    Tang WK; Ungvari GS
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):373-9. PubMed ID: 12691772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Incidence of the deficit form in refractory schizophrenia].
    Samuelian JC
    Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial of flupenthixol decanoate in chronic withdrawn schizophrenic patients.
    Vichaiya V
    J Med Assoc Thai; 1980 Apr; 63(4):205-9. PubMed ID: 6991627
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term treatment with flupentixol results of a post-marketing surveillance study.
    Messer T; Glaser T; Landen H; Schmauss M
    J Psychopharmacol; 2009 Sep; 23(7):805-13. PubMed ID: 18562418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zotepine in the treatment of negative symptoms in chronic schizophrenia.
    Fleischhacker WW; Barnas C; Stuppäck C; Unterweger B; Hinterhuber H
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):58-60. PubMed ID: 2883684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The positive and negative symptoms of schizophrenia: patterns of response to depot neuroleptic treatment.
    Martyns-Yellowe IS
    West Afr J Med; 1994; 13(4):200-3. PubMed ID: 7756183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care.
    Ritsner MS; Yorkov V; Ratner Y; Soifer P; Gibel A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1470-7. PubMed ID: 17669573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.